Conclusion
METASTATIC GASTRIC CANCER, GASTRIC CANCER
The addition of sorafenib to XP chemotherapy was safe but not more effective than XP alone for first‐line treatment of metastatic gastric cancer.In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first‐line chemotherapy in advanced gastric cancer. The combination of sorafenib and XP was feasible and well tolerated, but it did not show any differences in efficacy outcomes compared with standard XP. Further investigation of this combination regimen is not warranted in GC, at least in the first‐line setting, if patients are not selected by definite biomarkers.
